CR20210109A - INHIBICIÓN DE LA INTEGRINA av ß6 - Google Patents

INHIBICIÓN DE LA INTEGRINA av ß6

Info

Publication number
CR20210109A
CR20210109A CR20210109A CR20210109A CR20210109A CR 20210109 A CR20210109 A CR 20210109A CR 20210109 A CR20210109 A CR 20210109A CR 20210109 A CR20210109 A CR 20210109A CR 20210109 A CR20210109 A CR 20210109A
Authority
CR
Costa Rica
Prior art keywords
compounds
ανβ6
assay
evaluate
integrin
Prior art date
Application number
CR20210109A
Other languages
English (en)
Inventor
Matthew G Bursavich
Dawn M Troast
fu-yang Lin
Brian Sosa
Mats A Svensson
James E Dowling
Aleksey I Gerasyuto
Qi Qiao
Andrea Bortolato
Eugene Hickey
Bryce A Harrison
Blaise S Lippa
Kristopher N Hahn
Kyle D Konze
Tyler Day
Bruce N Rogers
Byungchan Kim
Cheng Zhong
Original Assignee
Morphic Therapeutic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphic Therapeutic Inc filed Critical Morphic Therapeutic Inc
Publication of CR20210109A publication Critical patent/CR20210109A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen inhibidores de molécula pequeña de la integrina ανβ6, y métodos para usarlos para tratar una serie de enfermedades y afecciones. Los solicitantes han descubierto nuevos compuestos inhibidores de la integrina ανβ6 y han evaluado la posesión, el rendimiento y la utilidad de ejemplos representativos de tales compuestos, tanto para la potencia bioquímica (por ejemplo, mediante el uso del ensayo del Ejemplo 35 para evaluar los ensayos de polarización de fluorescencia de compuestos para la unión de ανβ6) como las propiedades de permeabilidad in vitro (por ejemplo, mediante el uso del ensayo del Ejemplo 36 para evaluar la permeabilidad en MDCK).
CR20210109A 2018-08-29 2019-08-29 INHIBICIÓN DE LA INTEGRINA av ß6 CR20210109A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862724423P 2018-08-29 2018-08-29
US201962859457P 2019-06-10 2019-06-10
PCT/US2019/048782 WO2020047239A1 (en) 2018-08-29 2019-08-29 INHIBITING αV β6 INTEGRIN

Publications (1)

Publication Number Publication Date
CR20210109A true CR20210109A (es) 2021-06-24

Family

ID=67809398

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210109A CR20210109A (es) 2018-08-29 2019-08-29 INHIBICIÓN DE LA INTEGRINA av ß6

Country Status (22)

Country Link
US (4) US20200071322A1 (es)
EP (2) EP3617206A1 (es)
JP (1) JP7540998B2 (es)
KR (1) KR20210065935A (es)
CN (1) CN112805001B (es)
AU (1) AU2019327475A1 (es)
BR (1) BR112021003859A2 (es)
CA (1) CA3109534A1 (es)
CL (1) CL2021000484A1 (es)
CO (1) CO2021002706A2 (es)
CR (1) CR20210109A (es)
DO (1) DOP2021000035A (es)
EC (1) ECSP21013620A (es)
IL (1) IL280782A (es)
MA (1) MA51066A (es)
MX (1) MX2021002181A (es)
PE (1) PE20211640A1 (es)
PH (1) PH12021550404A1 (es)
SG (1) SG11202101913PA (es)
TW (1) TW202035400A (es)
UY (1) UY38353A (es)
WO (1) WO2020047239A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109996541A (zh) 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法
RU2769702C2 (ru) 2017-02-28 2022-04-05 Морфик Терапьютик, Инк. Ингибиторы интегрина avb6
EP3589285A4 (en) 2017-02-28 2020-08-12 Morphic Therapeutic, Inc. INHIBITORS OF INTEGRIN (ALPHA-V) (BETA-6)
TW201938158A (zh) 2018-03-07 2019-10-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
EP3617206A1 (en) 2018-08-29 2020-03-04 Morphic Therapeutic, Inc. Integrin inhibitors
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
JP7214882B2 (ja) 2018-10-30 2023-01-30 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリン阻害剤としてのイミダゾピリジン誘導体
AU2019373240B2 (en) 2018-10-30 2023-04-20 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
US11224600B2 (en) 2018-10-30 2022-01-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
CA3115830C (en) 2018-10-30 2023-09-12 Gilead Sciences, Inc. Compounds for inhibition of .alpha.4.beta.7 integrin
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin
AU2021339808A1 (en) * 2020-09-11 2023-04-06 Arrowhead Pharmaceuticals, Inc. Skeletal muscle delivery platforms and methods of use
EP4247472A4 (en) 2020-11-19 2024-10-09 Pliant Therapeutics Inc INTEGRIN INHIBITOR AND ITS USES
WO2024173570A1 (en) * 2023-02-14 2024-08-22 Morphic Therapeutic, Inc. INHIBITING αvβ8 INTEGRIN
WO2024173572A1 (en) * 2023-02-14 2024-08-22 Morphic Therapeutic, Inc. INHIBITING α vβ8 INTEGRIN

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4134467A1 (de) 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0612313A1 (en) 1991-11-14 1994-08-31 Glaxo Group Limited Piperidine acetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
WO1993014077A1 (en) 1992-01-21 1993-07-22 Glaxo Group Limited Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
ES2134870T3 (es) 1993-05-01 1999-10-16 Merck Patent Gmbh Antagonistas del receptor de adhesion.
US6069143A (en) 1994-12-20 2000-05-30 Smithkline Beecham Corporation Fibrinogen receptor antagonists
US20010034445A1 (en) 1995-12-29 2001-10-25 Smithkline Beecham Corporation Vitronectin receptor antagonists
BR9612378A (pt) 1995-12-29 1999-07-13 Smithkline Beecham Corp Antagonistas receptores de vitronectina
IL125030A0 (en) 1995-12-29 1999-01-26 Smithkline Beecham Corp Vitronectin receptor antagonists
CA2242877A1 (en) 1996-01-16 1997-07-24 Merck & Co., Inc. Integrin receptor antagonists
EP0796855B1 (de) 1996-03-20 2002-02-06 Hoechst Aktiengesellschaft Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
CZ291647B6 (cs) 1996-03-29 2003-04-16 Pfizer Inc. 6-Fenylpyridyl-2-aminové deriváty, jejich použití a farmaceutické kompozice na jejich bázi
CA2263999A1 (en) 1996-08-29 1998-03-05 Merck & Co., Inc. Integrin antagonists
DE69720771T2 (de) 1996-10-30 2004-01-29 Merck & Co Inc Integrin antagonist
US5952341A (en) 1996-10-30 1999-09-14 Merck & Co., Inc. Integrin antagonists
JP2001524079A (ja) 1997-04-07 2001-11-27 メルク エンド カンパニー インコーポレーテッド ガンの治療方法
WO1998046220A1 (en) 1997-04-14 1998-10-22 Merck & Co., Inc. Combination therapy for the prevention and treatment of osteoporosis
CA2309204A1 (en) 1997-11-26 1999-06-03 Dupont Pharmaceuticals Company 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as .alpha.v.beta.3 antagonists
JP2002508326A (ja) 1997-12-17 2002-03-19 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
HUP0100397A3 (en) 1997-12-17 2002-10-28 Merck & Co Inc Tetrahydro- or octahydrobenzonaphtyridin and quinolin derivatives, pharmaceutical compositions thereof and process for their preparation
US6017926A (en) 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
US6048861A (en) 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
ATE298338T1 (de) 1997-12-17 2005-07-15 Merck & Co Inc Integrin-rezeptor-antagonisten
JP2002508323A (ja) 1997-12-17 2002-03-19 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
EP1100506A4 (en) 1998-07-29 2002-06-26 Merck & Co Inc INTEGRIN RECEPTOR ANTAGONISTS
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
CA2355874A1 (en) 1998-12-19 2000-06-29 Merck Patent Gesellschaft Mit Beschraenkter Haftung .alpha.v.beta.6 integrin inhibitors
AU747503B2 (en) 1999-02-03 2002-05-16 Merck & Co., Inc. Benzazepine derivatives as alpha-V integrin receptor antagonists
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
AU749351B2 (en) 1999-06-02 2002-06-27 Merck & Co., Inc. Alpha V integrin receptor antagonists
AU748949B2 (en) 1999-06-23 2002-06-13 Merck & Co., Inc. Integrin receptor antagonists
DE19933173A1 (de) 1999-07-15 2001-01-18 Merck Patent Gmbh Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
GB9929988D0 (en) 1999-12-17 2000-02-09 Celltech Therapeutics Ltd Chemical compounds
WO2001053297A1 (en) 2000-01-20 2001-07-26 Merck & Co., Inc. Alpha v integrin receptor antagonists
WO2001053262A1 (en) 2000-01-24 2001-07-26 Merck & Co., Inc. Alpha v integrin receptor antagonists
JP2004511434A (ja) 2000-06-15 2004-04-15 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
DE10041423A1 (de) 2000-08-23 2002-03-07 Merck Patent Gmbh Biphenylderivate
AU2001290772A1 (en) 2000-09-14 2002-03-26 Merck And Co., Inc. Alpha v integrin receptor antagonists
AU9259801A (en) 2000-09-14 2002-03-26 Merck & Co Inc Alpha v integrin receptor antagonists
JP2004508401A (ja) 2000-09-18 2004-03-18 メルク　エンド　カムパニー　インコーポレーテッド シクロオキシゲナーゼ−２阻害剤およびインテグリンアルファ−ｖアンタゴニストの組合せを用いる炎症の治療
NZ539682A (en) 2001-01-29 2006-03-31 Dimensional Pharm Inc Substituted indoles and their use as integrin antagonists
DE10112771A1 (de) 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta¶6¶
US7109191B2 (en) 2001-05-03 2006-09-19 Merck & Co., Inc. Benzazepinone alpha vintegrin receptor antagonists
US20040043988A1 (en) 2001-06-15 2004-03-04 Khanna Ish Kurmar Cycloalkyl alkanoic acids as intergrin receptor antagonists
DE10204789A1 (de) 2002-02-06 2003-08-14 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta6
US20040077684A1 (en) 2002-08-16 2004-04-22 Bart De Corte Piperidinyl compounds that selectively bind integrins
FI20041129A0 (fi) 2004-08-30 2004-08-30 Ctt Cancer Targeting Tech Oy Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi
AR059224A1 (es) 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
US20080045521A1 (en) 2006-06-09 2008-02-21 Astrazeneca Ab Phenylalanine derivatives
US8367709B2 (en) 2007-06-13 2013-02-05 Bristol-Myers Squibb Company Dipeptide analogs as coagulation factor inhibitors
ES2428896T3 (es) 2007-11-16 2013-11-12 Ube Industries, Ltd. Compuesto de benzacepinona
US20120289481A1 (en) 2011-05-13 2012-11-15 O'neil Jennifer Compositions and methods for treating cancer
JP6215324B2 (ja) 2012-07-18 2017-10-18 セントルイス ユニバーシティ インテグリンアンタゴニストとしてのβアミノ酸誘導体
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
EP2784511A1 (en) 2013-03-27 2014-10-01 Universität Zürich Integrin alpha-v-beta6 for diagnosis/prognosis of colorectal carcinoma
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
WO2015103643A2 (en) 2014-01-06 2015-07-09 The General Hospital Corporation Integrin antagonists
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
WO2015179823A2 (en) 2014-05-23 2015-11-26 The California Institute For Biomedical Research Lung localized inhibitors of alpha(v)beta 6
WO2016022851A1 (en) 2014-08-06 2016-02-11 Children's Medical Center Corporation Modified integrin polypeptides, modified integrin polypeptide dimers, and uses thereof
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
US9790222B2 (en) 2015-02-19 2017-10-17 Scifluor Life Sciences, Inc. Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
SG10201902609TA (en) 2015-03-25 2019-04-29 Fujifilm Corp Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same
AU2016255494A1 (en) 2015-04-30 2017-11-02 Scifluor Life Sciences, Inc. Tetrahydronaphthyridinyl propionic acid derivatives and uses thereof
CA3008023A1 (en) 2015-12-30 2017-07-06 Saint Louis University Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
GB201604589D0 (en) 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604681D0 (en) * 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604680D0 (en) * 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
KR20190026001A (ko) 2016-07-05 2019-03-12 더 락커펠러 유니버시티 테트라하이드로나프티리딘펜탄아미드 인테그린 길항물질
CN109996541A (zh) 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法
EA201991102A1 (ru) 2016-11-01 2019-09-30 Эрроухед Фармасьютикалс, Инк. Альфа-v бета-6 лиганды интегрина и варианты их применения
WO2018085552A1 (en) 2016-11-02 2018-05-11 Saint Louis University Integrin antagonists
WO2018085578A1 (en) 2016-11-02 2018-05-11 Saint Louis University Integrin inhibitors in combination with an agent which interacts with a chemokine receptor
MA46746A (fr) 2016-11-08 2019-09-18 Bristol Myers Squibb Co Amides d'azole et amines en tant qu'inhibiteurs d'intégrine alpha v
MA46744A (fr) 2016-11-08 2019-09-18 Bristol Myers Squibb Co Composés mono et spirocycliques contenant du cyclobutane et de l'azétidine en tant qu'inhibiteurs de l'intégrine alpha v
WO2018089357A1 (en) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company INDAZOLE DERIVATIVES AS αV INTEGRIN ANTAGONISTS
HUE053620T2 (hu) 2016-11-08 2021-07-28 Bristol Myers Squibb Co Pirrol amidok mint alfa-V integrin inhibitorok
DK3538525T3 (da) 2016-11-08 2022-08-29 Bristol Myers Squibb Co 3-substituerede propionsyrer som alpha-v-integrinhæmmere
EP3558303A4 (en) 2016-12-23 2020-07-29 Pliant Therapeutics, Inc. AMINO ACID COMPOUNDS AND METHOD FOR USE
EP3562826A4 (en) 2016-12-29 2020-08-26 Saint Louis University INTEGRINANTAGONISTS
RU2769702C2 (ru) 2017-02-28 2022-04-05 Морфик Терапьютик, Инк. Ингибиторы интегрина avb6
EP3589285A4 (en) 2017-02-28 2020-08-12 Morphic Therapeutic, Inc. INHIBITORS OF INTEGRIN (ALPHA-V) (BETA-6)
TW201938158A (zh) 2018-03-07 2019-10-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
WO2020009889A1 (en) 2018-07-03 2020-01-09 Saint Louis University ALPHAvBETA1 INTEGRIN ANTAGONISTS
WO2020047207A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutics, Inc. Inhibitors of (alpha-v)(beta-6) integrin
EP3844162A4 (en) 2018-08-29 2022-05-25 Morphic Therapeutic, Inc. INHIBITORS OF AV-BETA6 INTEGRIN
EP3617206A1 (en) 2018-08-29 2020-03-04 Morphic Therapeutic, Inc. Integrin inhibitors
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
EP3952902A4 (en) 2019-04-08 2022-12-21 Pliant Therapeutics, Inc. DOSAGE FORMS AND TREATMENT SCHEMES FOR AMINO ACID COMPOUNDS

Also Published As

Publication number Publication date
WO2020047239A1 (en) 2020-03-05
PH12021550404A1 (en) 2021-10-04
US20220073511A1 (en) 2022-03-10
IL280782A (en) 2021-04-29
BR112021003859A2 (pt) 2021-05-18
MA51066A (fr) 2020-10-14
CO2021002706A2 (es) 2021-05-20
CL2021000484A1 (es) 2021-09-03
CA3109534A1 (en) 2020-03-05
MX2021002181A (es) 2021-07-15
DOP2021000035A (es) 2021-06-30
CN112805001A (zh) 2021-05-14
US20200071322A1 (en) 2020-03-05
JP7540998B2 (ja) 2024-08-27
ECSP21013620A (es) 2021-05-31
EP4086254A1 (en) 2022-11-09
JP2021535141A (ja) 2021-12-16
US20200354359A1 (en) 2020-11-12
US20200385384A1 (en) 2020-12-10
US11739087B2 (en) 2023-08-29
CN112805001B (zh) 2024-07-23
TW202035400A (zh) 2020-10-01
US11021480B2 (en) 2021-06-01
SG11202101913PA (en) 2021-03-30
KR20210065935A (ko) 2021-06-04
PE20211640A1 (es) 2021-08-24
UY38353A (es) 2020-03-31
AU2019327475A1 (en) 2021-03-11
EP3617206A1 (en) 2020-03-04

Similar Documents

Publication Publication Date Title
PH12021550404A1 (en) INHIBITING aV á6 INTEGRIN
WO2020047207A8 (en) Inhibitors of (alpha-v)(beta-6) integrin
NZ754051A (en) Novel antibodies and uses thereof
UY29479A1 (es) Inhibidores de adn-pk
MX2010002783A (es) Proceso e intermediarios para la preparacion de inhibidores de integrasa.
CR9244A (es) AMINO-IMIDAZOLONAS PARA LA INHIBICION DE ß-SECRETASA
AU2020317609A8 (en) Novel heteroaryl-triazole compounds as pesticides
EA200800321A1 (ru) Ингибиторы гистондеацетилазы
BRPI0510412A (pt) compostos orgánicos
EA201101096A1 (ru) Способы выделения бактерий
BRPI0720525B8 (pt) inibidores de mapk/erk quinase
NO20091415L (no) Fremgangsmate og mellomprodukter for fremstilling av integraseinhibitorer
BRPI0816911A8 (pt) Processo para preparação de 4-aminobut-2-enolidas
AR054533A1 (es) Proceso y reactivo magnetico para la separacion de impurezas de los minerales
MY173526A (en) Novel anti-?5?1 antibodies and uses thereof
WO2008064304A3 (en) Compositions and methods for the identification of inhibitors of protein synthesis
CU20100099A7 (es) 5-[(3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas, un proceso para su producción y su uso como agentes antinflamatorios
CU20090009A7 (es) Bencilaminas, un proceso para su producción y su uso como agentes anti-inflamatorios
EP2197455A4 (en) COMPOSITIONS AND METHODS FOR IDENTIFYING INHIBITORS OF RETROVIRAL INFECTIONS
SG151207A1 (en) New process for the synthesis of strontium ranelate and its hydrates
WO2018160879A3 (en) Macromolecular corrosion (mcin) inhibitors: structures, methods of making and using the same
TW200801015A (en) Substituted aminophenylsulfonamide compounds as HIV protease inhibitor
DK2005190T4 (da) Inhibering af GASC1
DE602006008751D1 (de) Synthese von proteaseinhibitorvorstufen
EA200970361A1 (ru) Ингибиторы киназы